Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors

US9617257B2 · kind B2 · utility

Assignee

• Betta Pharmaceuticals Co., Ltd · CN

Inventors

• Shaojing Hu · Beijing, CN
• Fei Wang · Beijing, CN
• Zhiguo Xu · Beijing, CN
• Yanping Wang · Beijing, CN
• Yinxiang Wang · Beijing, CN

Key dates

• Filing date: Jul 1, 2013
• Grant date: Apr 11, 2017
• Expiry date: Jul 1, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders.